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Abstract
Background: Aflatoxin B1 (AFB1) contamination of food is very high in most sub-Saharan African countries. AFB1 is
known to cause hepatocellular carcinoma (HCC) by inducing mutation in the tumour suppressor gene TP53. The
number of new HCC cases is high in West Africa with an accompanying high mortality. The type I interferon (IFN)
pathway of the innate immune system limits viral infections and exerts its anti-cancer property by up-regulating
tumour suppressor activities and pro-apoptotic pathways. Indeed, IFN-α is reported to show significant protective
effects against hepatic fibrogenesis and carcinogenesis. However, the mechanism behind AFB1 deregulation of the
type I interferon (IFN) signalling pathway, with consequent HCC is largely unknown. This current study seeks to test
the hypothesis that AFB1 inhibits the type I IFN response by directly interfering with key signalling proteins and
thus increase the risk of HCC in humans.
Methods: We evaluated the effects of AFB1 on the type I IFN signalling pathway using IFN stimulated response
element (ISRE)-based luciferase reporter gene assay. In addition, the effects of AFB1 on the transcript levels of JAK1,
STAT1 and OAS3 were assessed by real-time quantitative polymerase chain reaction (RT-qPCR) and confirmed by
immunoblot assay.
Results: Our results indicated that AFB1 inhibited the type I IFN signalling pathway in human hepatoma cell line
HepG2 cells by suppressing the transcript levels of JAK1, STAT1 and OAS3. AFB1 also decreased the accumulation of
STAT1 protein.
Conclusion: The inhibition of the type I IFN anti-cancer response pathway by AFB1 suggest a novel mechanism by
which AFB1 may induce hepatocellular carcinoma in humans.
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Background
The innate immune response is activated within few
hours upon exposure of the human system to infectious
agents and other toxic chemical compounds such as my-
cotoxins and works to protect the individual against the
harmful effects of the chemical agents and the disease
causing microorganisms. One component of the innate
immune system that plays a key role in the first line of
defence in eliminating pathogens and tumour cells is the
IFN system. The type I IFNs for example in addition to
their antiviral properties have been employed in the
treatment of certain cancers such as Hairy cell
Leukemia, AIDS-related Kaposi’s sarcoma and other ma-
lignancies [1]. It has been reported that treatment of
cells with IFN leads to the activation of the tumour sup-
pressor gene p53 which plays a central role in the apop-
tosis of some tumour cells [1]. Indeed, Aziz and
co-workers showed in their study that IFN-α has a sig-
nificant protective effects against hepatic fibrogenesis
and carcinogenesis [2]. Therefore any substance being
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component of pathogen or chemical produced by micro-
organisms which tend to inhibit or suppress the type I
IFN will weaken the innate immune system and predis-
pose individuals to infections and cancers.
AFB1, a lethal mycotoxin produced by Aspergillus
flavus and Aspergillus parasiticus is a potent hepatocar-
cinogen in humans [3, 4] and in view of that it has been
classified as group 1 human carcinogen by the Inter-
national Agency for Research on Cancer (IARC) [5].
AFB1 contamination of diet coupled with subsequent
prolonged heavy exposure is a major risk factor for the
development of HCC. Food meant for human and ani-
mal consumption have been reported to contain high
levels of aflatoxins in some West African countries such
as Ghana, Togo, Nigeria and Benin [6–8] largely due to
sub-optimal farming practices, high humidity and poor
storage conditions. For example in Ghana 83.3% of wea-
nimix, food prepared locally from maize and groundnut
for children have been reported to have aflatoxin levels
higher than the national acceptable levels of 15 ppb [9].
Cereal based foods are staple in Ghana in particular and
sub-Saharan Africa in general, it means many more
people are exposed to high levels of aflatoxins and thus
increasing their risk of HCC.
The incidence of HCC in the West African sub region is
high with an annual death rate of about 200,000 [10]. In
fact West Africa is ranked second, aside Eastern Asia as
region affected most with HCC [10]. In West Africa, the
death rate of HCC is almost equal to its incidence with
most HCC sufferers dying within weeks of their diagnosis
indicating the aggressive and dangerous nature of HCC
[10, 11]. In addition to AFB1, other risk factors that con-
tribute to HCC include chronic HBV/HCV infection and
heavy alcohol consumption. Information available indi-
cates that the risk of HCC developing is amplified through
the synergistic effects of aflatoxin ingestion and HBV in-
fection. The risk of HCC in people with chronic HBV in-
fection and also exposed to aflatoxin is up to 30 times
greater than in individual exposed to either of the two fac-
tors only [12–14]. These two risk factors (aflatoxin and
HBV) are common in underdeveloped countries of the
world including Ghana [6, 15] suggesting that the risk of
HCC is likely to be high in Ghana.
The role of AFB1 in the pathogenesis of HCC, via muta-
tion in the tumour suppressor gene p53 has been well
established. However, information on how AFB1 could de-
regulate other anti-cancer pathways such as the type I IFN
signalling pathway as a way of causing HCC is very lim-
ited. This study was carried out to test the hypothesis that
AFB1 inhibits the type I IFN response pathway thus con-
tributing to the pathogenesis of HCC. Results from this
study could influence future therapeutic intervention for
AFB1-induced HCC and also broaden our knowledge of
the role of AFB1 in HCC immunobiology.
Methods
Reagents and chemicals
The AFB1 used in the study was purchased from Sigma-
Aldrich, USA (cat no A6636) and dissolved in dimethyl
sulfoxide (DMSO) to a stock concentration of 3200 μM.
The AFB1 stock solution was divided into aliquots,
wrapped in aluminium foil and stored frozen at −20 °C
until used. The AFB1 stock solution was diluted to the
desired concentration in normal growth medium when
necessary. The foetal bovine serum (FBS) was purchased
from Sigma-Aldrich, USA. Dulbecco’s Modified Eagles
Medium (DMEM) (high glucose, L-glutamine, sodium
pyruvate and 25 mM HEPES) was purchased from
Science Cell. Minimum essential medium (MEM) non-
essential amino acids was purchased from Sigma
Aldrich, USA while penicillin-streptomycin was pur-
chased from Gibco by Invitrogen, UK. Lipofectamine
2000 was purchased from Gibco by Life Technologies,
UK (cat no 11668-019). The human recombinant
interferon-alpha 2 (rIFN-α2) was purchased from PBL
interferon source (cat no 11115-1). The stock solution of
the human recombinant interferon-alpha 2 was diluted
to working concentration using phosphate buffered sa-
line containing 0.1% bovine serum albumen as a diluent.
The STAT1 (cat no PA5-34504) and GAPDH (cat no QE
212271) primary antibodies were purchased from
Thermo Scientific, USA. The secondary antibody conju-
gated to horse-radish peroxidase (cat no 31430) was pur-
chased from Thermo Scientific, USA.
Cell culture
The cells used in this study were kindly donated by Pro-
fessor David J. Blackbourn of the University of Surrey,
UK. The cell lines used were human hepatoma cell line
HepG2 (ECACC 85011430) and mouse fibroblast cell
line L929 (NCTC) (ECACC 85103115). The HepG2 and
the L929 cells were grown in DMEM high glucose con-
taining L-glutamine, sodium pyruvate and HEPES sup-
plemented with 10% v/v heat inactivated FBS, 1% v/v
MEM non-essential amino acids, 100 IU/ml of penicillin
and 100 μg/ml of streptomycin. The cultures were main-
tained at 37 °C in 5% carbon dioxide (CO2) under hu-
midified condition.
Cytotoxicity assay
HepG2 cells were grown to about 60% confluence and
then treated with increasing concentrations of AFB1
(0–3200 μM). Twenty four hours later, the AFB1 con-
taining medium was removed and fresh medium without
AFB1 was added. The cytotoxic effects was evaluated by
an MTS based assay using Cell Titre 96 AQueous One
Solution reagent (Promega, USA, cat no G358C) follow-
ing the manufacturer’s instruction.
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Transient transfections and luciferase assays in HepG2 cells
Dual luciferase assays were performed according to our
previous study [16]. Briefly, the cells were grown in du-
plicate wells of the 96-well plate until they reached
about 80% confluence. The plasmids used in this study
were kind gifts from Professor David J. Blackbourn
(University of Surrey, UK). The DNA, pISRE-luc used in
the study was extracted from E.coli strain HD5α using
EndoFree Maxi Prep Kit (Qiagen, USA) following the
manufacturer’s instruction. The pISRE-luc expresses the
firefly luciferase protein while pRLSV40 plasmid ex-
presses the Renilla luciferase. The Renilla was included
as internal control to which the pISRE-luc activity was
normalized. A transfection mixture was prepared by di-
luting the plasmids DNA (pISRE-luc 500 ng: pRLSV40
1 ng) in serum and antibiotic free media and incubated
at room temperature for 5 min. In addition, the Lipofec-
tamine 2000 was also diluted in serum and antibiotic
free media. After 5 min of incubation, the diluted DNA
and Lipofectamine 2000 were mixed and incubated at
room temperature for 20 min and then added to the
designated wells and incubated at 37 °C in 5% CO2
under humidified condition for 24 h.
For the experiment that involved the determination of
the minimum concentration of rIFN-α that would
induce the maximum activity of IFN-α-inducible pISRE-
luc activity, the transfected cells were stimulated with in-
creasing concentrations of rIFN-α (100-400 IU/ml).
Twenty four hours later, luciferase assays were per-
formed using the dual luciferase reporter assay system
(Promega, USA, cat no E1960) following the manufac-
turer’s protocol. After preparing the cell lysates, 20 μl of
the aliquot was employed for luminescence measure-
ment using Berthold Orion luminometer (Berthold
Detection Systems, Germany).
For the experiment that involved the determination of
the effects of AFB1 on the type 1 IFN signalling pathway,
the transfected cells were stimulated with rIFN-α
(400 IU/ml) and simultaneously treated with increasing
concentrations of AFB1 (0.8–32 μM). Twenty four hours
later, dual luciferase reporter gene assay was performed
as described above.
Reverse transcriptase-quantitative polymerase chain reaction
(RT-qPCR)
The cultured HepG2 cells were treated with AFB1 and
simultaneously stimulated with the rIFN-α for 24 h as
described above. Total RNA was then extracted using
Gene JET RNA purification kit (Thermo Scientific,
Germany) following the instructions of the manufac-
turer. The quantity and the purity of the total RNA was
verified by spectroscopy (Nano Drop 1000, Thermo
Scientific). The purity was later confirmed by 1% agarose
gel electrophoresis using ethidium bromide as stain.
Prior to the cDNA synthesis, any traces of genomic
DNA present in the total RNA was removed by treating
the total RNAs with double stranded (ds) DNase
(Thermo Scientific, Germany) at 37 °C for 2 min
followed by maintenance of the mixture on ice. The total
RNAs were converted to cDNA using Moloney Murine
Leukemia virus (M-Mul V) reverse transcriptase, oligo
(dT) and random hexamer primers in a final reaction
volume of 20 μl. The mixture was first incubated for
10 min at room temperature followed by further 15 min
of incubation at 50 °C. The entire cDNA synthesis reac-
tion was stopped by heating the mixture at 85 °C for
5 min. The cDNA was stored frozen at −80 °C until used
in the qPCR.
JAK1, STAT1 and OAS3 target genes were amplified
using the Maxima Probe/Rox qPCR master mix
(Thermo Scientific, Germany). The primers and probes
used were designed and synthesized by Biomers,
Germany (Table 1).
The primers and probes of the target genes and the
endogenous control (GAPDH) were labelled with differ-
ent fluorescent reporter dyes at the 5′ end and quencher
dyes at the 3′ end and this allowed the target genes to
be amplified in the same tube in a duplex qPCR
reaction.
After optimizing the primer and probe PCR condi-
tions, a duplex qPCR was performed in a 25 μl reaction
volume that contained 0.3 μM forward and reverse
primers of the target genes, 0.2 μM of the target probes,
0.1 μM forward and reverse primers of the GAPDH,
0.2 μM of the GAPDH probe and 2.5 μl of 1:10 dilution
Table 1 Sequences of probes and primers
Name of gene Sequence of primers and probes Fluorophores
JAK1 Probe: 5′AGCAGTCAGTGTGGCG
TCATTCTCC-3′
Forward primer 5′- CAATTGGCAT
GGAACCAACGAC-3′
Reverse primer 5′-CAAATCATACT
GTCCCTGAGCAAAC-3′
5′ FAM- 3′ BHQ-1
STAT1 Probe: 5′-CGCTCTGCTGTCTCCGC
TTCCACTCC-3′
Forward primer: 5′GTTGCTGAATGT
CACTGAACTTACC-3′
Reverse primer: 5′- AGCTGATCCAA
GCAAGCATTGG-3′
5′ FAM- 3′ BHQ-1
OAS3 Probe 5′- AGCCTGGTGCCTGCCTTC
AATGTCC-3′
Forward primer: 5′-TCCGCCTGACA
TCCGTAGATC-3′
Reverse primer: 5′-TCCTCCGCAGCT
CTGTGAAG-3′
5′ FAM- 3′ BHQ-1
GAPDH Probe: 5′- CCGTTGACTCCGACCTTC
ACCTTCC-3′
Forward primer: 5′- AGCCACATCGCT
CAGACACC-3′
Reverse primer: 5′- TGACCAGGCGCC
CAATACG-3′
5′HEX- 3′TAMRA
Narkwa et al. Infectious Agents and Cancer  (2017) 12:17 Page 3 of 9
of the cDNA samples. The qPCR cycling conditions
were as follows: 95 °C for 10 min for the first cycle (ini-
tial denaturation), 95 °C for 15 s for 40 cycles (denatur-
ation) and 60 °C for 60 s for 40 cycles (annealing/
extension). The qPCR reaction products were analyzed
using Bio-Rad CFX 96 manager software (Bio-Rad,
USA). The relative quantification of the target genes was
calculated using the comparative CT method. The rela-
tive quantities of JAK1, STAT1 and OAS3 after
normalization to the endogenous control (GAPDH) was
given by 2 -ΔΔCT as previously described [17].
Western blotting
To examine the effects of AFB1 on the protein accumu-
lation of STAT1, the cultured HepG2 cells were treated
with AFB1 and simultaneously stimulated with the rIFN-
α for 24 h as described above. The cells were later har-
vested and lysed to extract total proteins using cold
Radioimmunoprecipitation assay (RIPA) buffer (Thermo
Scientific, Germany) containing freshly added protease
and phosphatase inhibitor cocktails and ethylenedi-
aminetetraacetic acid (EDTA) (Thermo Scientific,
Germany) following a standard protocol. Aliquots of the
protein samples were mixed with 2X sample buffer con-
taining 2-beta mercaptoethanol and the mixture was
heated for 5 min at 95 °C to denature the proteins. The
proteins were separated by 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and
then blotted onto 0.45 μM pore size polyvinylidene
difluoride (PVDF) membranes (Bio-Rad Laboratories).
The PVDF membranes were blocked in 5% non-fat dried
milk in 1X Tris buffered saline with Tween-20 (TBST)
before being incubated separately with STAT1 and
GAPDH primary antibodies. Primary antibodies were
used at the following dilutions: STAT1 (1:1000 dilution)
and GAPDH (1:2500 dilution). The membranes were
then incubated with the primary antibodies at 4 °C over-
night. The secondary antibodies conjugated to horserad-
ish peroxidase (Thermo Scientific, USA) were used at a
dilution of 1:5000. The membranes were probed with
the secondary antibody at room temperature with gentle
shaking for 1 h after which bands were visualized by per-
forming enhanced chemiluminescence using Pierce en-
hanced chemiluminescence (ECL) western blotting
substrate (Thermo Scientific, USA). The images were
captured with C-DIGIT blot scanner (Li-COR Bio-
science, USA) and analyzed using image J software.
Results
Cytotoxic effects of AFB1 and IFN concentration course
The AFB1 is an extremely toxic compound which could
not have been used directly on the cells. Therefore, the
concentration of AFB1 that was not toxic to the HepG2
cells was determined using MTS based assay as
described above. As shown in Fig. 1a, AFB1 killed the
HepG2 cells in a dose-dependent fashion after expos-
ure to concentrations up to 3200 μM for 24 h
followed by maintenance of cells in AFB1 free media
for 24, 48 and 72 h. The experiment established up
to 10 μM of AFB1 was not toxic to the cells and was
therefore used in subsequent experiments. Next the
concentration of rIFN-α required to induce maximal
activity of the type I IFN response pathway was deter-
mined. It was observed that the pISRE-luc activity (a
measure of the type I interferon activity) increased
with increasing concentration of rIFN-α and peaked
at concentrations of 200-400 IU/ml (Fig. 1b).
AFB1 suppresses IFN-α induced ISRE signalling
To measure the effect of AFB1 on the anti-cancer activ-
ity of the type I IFN response pathway, a luciferase re-
porter gene expressing pISRE-luc was employed. The
pathway activation was induced with rIFN-α (400 IU/
ml) through the transactivation of interferon stimulated
response elements (ISRE). It is already established that
the pathway is activated following the binding of IFN-α
to the IFN-α receptors R1 and R2 on cells to trigger cas-
cades of events leading to the transactivation of the ISRE
as reviewed in Randall and Goodbourn [18].
The cultured HepG2 cells were stimulated with
rIFN-α and simultaneously treated with AFB1 as de-
scribed above. As shown in Fig. 2, the activated path-
way peaked at about five-fold above background or
basal levels (see fourth bar; Fig. 2). It was noted that
AFB1 did not influence the pathway activity in anyway
because cells treated with AFB1 alone showed same
background level of pathway activity as those cells in
which the pathway was not activated; the so called
‘none treated cells’ (see first bar; Fig. 2).
The addition of AFB1 to the cells in which the type I
IFN response pathway was activated saw AFB1 dose
dependent inhibition of the pathway activity up to 54.8%
in cells treated with 10 μM of AFB1 and 68.2% in cells
treated with 32 μM respectively (Fig. 2). The pathway ac-
tivity was measured by the firefly luciferase pISRE-luc
activities (Fig. 2).
The concentration of AFB1 and rIFN-α used in the
experiment were chosen based on the following: (i) at
10 μM of AFB1 ≥ 90% of the cells survived (Fig. 1a),
(ii) between 200 and 400 IU/ml of rIFN-α induced
the maximum activity of IFN-α inducible ISRE pro-
moter i.e. a measure of the type I IFN response path-
way (Fig. 1b). In the subsequent experiments, 10 μM
of AFB1 was used and that concentration was selected
based on the fact it had the capacity to significantly
inhibit the type I IFN induced signalling in HepG2
cells as measured by the firefly luciferase pISRE-luc
activities (p-value ≤ 0.047) (Fig. 2).
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AFB1 inhibits transcripts expression of JAK1, STAT1 and
OAS3 genes
Having demonstrated at the luciferase reporter gene assay
level that AFB1 inhibits the type I IFN response signalling
pathway, the next task was to test our hypothesis that
AFB1 would inhibit the transcripts of key signalling ele-
ments of the pathway. The JAK-STAT-ISRE arm of the
type I IFN response pathway was chosen for the study be-
cause when activated it leads to the activation of inter-
feron responsive genes such as OAS3 whose inhibition by
AFB1 was hypothesized in the current study.
RT-qPCR analysis of the transcripts levels of JAK1,
STAT1 and OAS3 genes in the cultured HepG2 cells
stimulated with or without rIFN-α (400 IU/ml) and sim-
ultaneously treated with or without AFB1 (10 μM) was
performed.
The cells in which the pathway was activated showed
about 3-fold increase in the transcripts levels of JAK1
compared to background or basal levels. However, when
AFB1 was added to the cells in which the pathway was
activated the transcripts levels of JAK1 reduced to al-
most half (49.1%, p-value ≤ 0.0001).
Fig. 2 AFB1 inhibits IFN-α induced ISRE signalling in a dose dependent fashion. HepG2 cells were cultured at density of 5 × 104 cells per well of
the 96-well plate until they reached 80% confluence. The cells were transiently co-transfected with pISRE-luc (500 ng) and pRLSV40 (1 ng). The
pRL40-luc which constitutively expresses the Renilla luciferase was included as internal control to which pISRE-luc activity was normalized. At 24 h
post-transfection, the cells were stimulated with or without rIFN-α and simultaneously treated with or without AFB1. Transfected cells which were
stimulated with rIFN-α but not treated with AFB1 were calculated to have 100% pISRE-luc activity. The data are presented as mean normalized
pISRE-luc activity and the standard deviation of three independent experiments each conducted in duplicate wells. There was a significant difference
in pISRE-luc activity of cells stimulated with rIFN-α alone compared to cells stimulated with rIFN-α and simultaneously treated with 10 μM of AFB1
(p-value≤ 0.047)
Fig. 1 Establishing the maximum non-toxic concentration of AFB1 and maximum inducible concentration of rIFN-α (a) HepG2 cells were cultured
at density of 5 × 104 cells per well of the 96-well plate until they reached 60% confluence. The cells were then treated with or without increasing
amount of AFB1 (0–3200 μM) for 24 h after which the AFB1 containing media were replaced with fresh media. Cytotoxicity was evaluated by
MTS-based assay at 24, 48 and 72 h. The viability of cells was calculated as ratio between AFB1 treated cells and non-treated cells. Data are presented
as mean and standard deviation of three independent experiments each performed in duplicate wells, p-value≤ 0.977 as determined by one-way
ANOVA. b Establishing the maximal IFN-α induction of ISRE driven luciferase reporter gene activity. HepG2 cells were cultured at density of 5 × 104 cells
per well of the 96-well plate until they reached 80% confluence. The cells were transiently co-transfected with pISRE-luc (500 ng) and pRLSV40 (1 ng).
At 24 h post-transfection, the cells were treated with increasing concentration of rIFN-α. Luciferase activity was measured 24 h later. The data are
presented as mean and the standard deviation of three independent experiments each conducted in duplicate wells. There was no significant
difference in pISRE-luc activity of cells treated with 300 and 400 IU/ml of rIFN-α (p-value≤ 0.7527)
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Although the pathway activities in those experiments
to assess the effect of STAT1 and OAS3 transcripts levels
showed over 10-fold above background levels, similar
pattern of results were seen for STAT1 and OAS3 be-
cause the transcripts levels were reduced by AFB1 to
47% (p-value ≤ 0.03) and 39% (p-value ≤ 0.05) respect-
ively (Fig. 3b & c).
Taken together, it was observed that AFB1 signifi-
cantly inhibited the mRNA expression levels of JAK1,
STAT1 and OAS3 genes (Fig. 3). To be sure that
HepG2 cells were responding to rIFN-α treatment
and that the ISRE was functioning, a parallel experi-
ment in which HepG2 cells were transiently trans-
fected with pISRE-luc and pRLSV40-luc as described
in Fig. 2 was conducted. At the time of harvest of
the cells for RT-qPCR, aliquots of cell lysates from
the parallel experiments were assayed for dual lucifer-
ase activity and the inhibition of ISRE activity was
confirmed as described in Fig. 2 (data not shown).
AFB1 inhibits STAT1 protein synthesis
Different post-transcriptional events could be involved
in translating mRNAs into proteins [19] suggesting that
lower mRNA levels might not necessarily corresponds to
lower protein expression and vice versa. Therefore, west-
ern blot assay was employed to ascertain whether the in-
hibition of the mRNA expression level of STAT1 by
AFB1 would ultimately affect its translation into proteins
as well (see Fig. 3).
Again the cultured HepG2 cells were stimulated and
treated as described in Fig. 3. Protein extracts of HepG2
cells stimulated with or without rIFN-α and treated with
AFB1 (10 μM) were analysed by western blotting for
STAT1 using Glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) as a loading control. Briefly, cell lysates
were prepared and thereafter, protein samples were sep-
arated on SDS-PAGE and immunoblotted with anti
STAT1 and anti-GAPDH antibodies respectively. In
order to ensure that the cells were functionally respond-
ing to stimulation and treatment at the time when the
lysates were prepared, a parallel experiment in which the
cells were transiently transfected with pISRE-luc and
pRLSV40 as described in Fig. 3 were assayed for dual lu-
ciferase activity and the inhibition of the type I IFN re-
sponse pathway activity by AFB1 was confirmed (data
not shown).
Consistent with the results shown in Fig. 3, STAT1 ac-
cumulation peaked in cells in which the type I IFN path-
way was activated in the absence of AFB1 (see Fig. 4;
band 2 from right). However, on the contrary the STAT1
accumulation was substantially reduced in cells in which
the pathway was activated in the presence of AFB1 (see
Fig. 4; band 1 from right). Again, cells in which the type
I IFN pathway was not activated showed low back-
ground levels of STAT1 presence (see Fig. 4; bands 1
and 2 from left). Also consistent with Fig. 3 the protein
levels of GAPDH were not affected by AFB1 as their
levels were shown to be equal in all cells regardless of
the AFB1 treatment or stimulation with rIFN-α.
Discussion
AFB1 is a potent hepatocarcinogen [3, 4] which when
ingested is metabolized by CYP450 class of enzymes in
the liver to AFB1, 8-9 exo epoxide [3, 4]. The AFB1 8-9
exo epoxide binds DNA and induces AGG to AGT
transversion mutation at codon 249 in the tumour
Fig. 3 AFB1 inhibits the mRNA expression levels of the JAK1 (a), STAT1 (b) and OAS3. c. HepG2 cells were cultured at density of 5 × 10
4 cells per
well of the 6-well plate until they reached 80% confluence. The cells were stimulated with or without rIFN-α (400 IU/ml) and simultaneously treated
with or without AFB1 (10 μM) for 24 h. Total RNA was extracted and reverse transcribed to cDNA using random primers. Quantitative PCR was
performed with gene specific primers and probes for JAK1, STAT1 and OAS3 respectively. The relative levels of JAK1, STAT1 and OAS3 after
normalization to GAPDH (endogenous control) was plotted. The relative levels of JAK1, STAT1 and OAS3 were calculated using the 2-ΔΔCt
(Livak) method. These results are presented as mean and standard deviations of three independent experiments each performed in triplicate wells;
JAK1 (p-value≤ 0.0001), STAT1 (p-value≤ 0.03) and OAS3 (p-value≤ 0.05)
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suppressor gene p53 [20, 21]. This mutation leads to the
inhibition of the p53 mediated transcription and under-
lines the mechanism by which AFB1 causes HCC [22]. It
must be stated however that, the mechanism by which
AFB1 causes HCC may not be limited to p53 mutation
alone and that AFB1 may also induce cancers by deregu-
lating other anticancer signalling pathways. For example
Ubagai et al. [23] demonstrated that AFB1 may also in-
duce tumourigenesis by deregulating the insulin-like
growth factor 1 receptor (IGF-IR) signalling pathway
suggesting that AFB1 may also induce tumourigenesis by
deregulating other anticancer pathways such as the type
I IFN signalling pathway. In this study we tested the hy-
pothesis that AFB1 would suppress/inhibit the type I
IFN signalling pathway and thus provide another mech-
anism by which AFB1 may cause cancer. Findings from
the current study in which AFB1 was shown to inhibit
the type 1 IFN response pathway by targeting the key
signalling elements are consistent with that of Jiang et
al. [24] who reported that AFB1 inhibited the mRNA ex-
pression levels of IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ
and TNF-α in the small intestines of broilers treated
with AFB1. Moreover, AFB1 has also been reported to in-
hibit mRNA and protein expression levels of IL-4, IL-6,
IL-10 in the peritoneal macrophages and splenic
lymphocyte cell lines [25, 26] and STAT5A gene mRNA
expression levels in bovine mammary epithelial cells
[27]. One way by which the type I IFN signalling re-
sponse exerts its anti-cancer and antiviral response is
through the activation of the JAK-STAT-ISRE arm of the
pathway. One component of the JAK-STAT-ISRE signal-
ling pathway considered to have tumour suppressor
function is STAT1 [28]. When activated, STAT1 sup-
presses tumour development by inducing apoptosis [29]
and also inhibit tumour angiogenesis [30]. Therefore the
suppression of STAT1 by AFB1 at the both transcription
and translational levels as demonstrated in the current
study will impair the ability of STAT1 in orchestrating
the expression of myriad of genes which are required to
promote apoptosis, inhibit cell proliferation and angio-
genesis in response to AFB1.
The activation of the JAK-STAT-ISRE arm of the type
I IFN signalling pathway results in the activation of the
so called interferon responsive elements including the
OAS3, PKR, Mx etc as reviewed in Randall and Good-
bourn [18]. The OAS3 pathway when activated leads to
the establishment of antiviral state by inhibiting protein
synthesis which culminates in the destruction of both
viruses and infected cells [31, 32]. The OAS3 has also
been reported to play a role in inhibiting tumour devel-
opment by inducing apoptosis and anti-proliferative re-
sponses [33, 34]. The activation of the JAK-STAT-ISRE
signalling pathway starts upon the phosphorylation and
activation of JAK1 and TYK2 when the correct ligands
Fig. 4 AFB1 inhibits STAT1 protein synthesis. HepG2 cells were cultured at density of 5 × 10
4 cells per well of the 6-well plate until they reached
80% confluence. The cells were stimulated and treated as described above. After blotting, the membranes were immunoblotted with antibody
against the STAT1 epitope of the STAT1 protein as primary antibody followed by horseradish peroxidase conjugated goat anti-rabbit antibody as
secondary antibody. The membranes were also probed for GAPDH which was used as endogenous control. The dilutions of the primary antibodies
used against STAT1 and GAPDH proteins were as follows: STAT1 (Thermo Scientific, cat no PA5-34504; 1:1000), GAPDH (Thermo Scientific, cat
no QE212271; 1:2500). The secondary antibody used was polyclonal goat anti-Rabbit conjugated to HRP (Thermo Scientific, cat no PI31460, 1: 5000).
The blotted membranes were developed using enhanced chemiluminescence reagents and the protein bands were detected and captured with
C-DIGIT blot scanner imaging device. (a) The relative STAT1 protein intensity was quantified using Image J software package. (b) Western blot analysis
of STAT1 protein. (c) Western blot analysis of GAPDH protein as loading control
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bind to the IFNAR (Fig. 5). The activated JAK1 and
TYK2 in turn phosphorylate STAT1 and STAT2 setting
in motion a cascade of events which finally initiates
the transcription of IFN-inducible genes switching on
the anti-cancer and anti-viral effects as reviewed in
Randall and Goodbourn [18]. Therefore, any stimulus
which deregulates the expression of either JAK1 or
TYK2 could potentially deregulate the entire type I
IFN response signalling pathway and thereby weaken
the immune system and thus predispose individuals
to infections and or cancer.
Taken together, the current study has revealed for the
first time the inhibition of the type I IFN response path-
way by AFB1 via the inhibition of the transcripts of
JAK1, STAT1 and OAS3 and also inhibit the protein ac-
cumulation of STAT1. The findings of the current study
could be another mechanism by which AFB1 may cause
HCC (Fig. 5).
Conclusions
In conclusion the current study has shown that AFB1
down-regulated the type I IFN response pathway by
significantly inhibiting the key signalling elements
such as JAK1, STAT1 and OAS3 and also the STAT1
protein. Findings from this study reveals the negative
effects of AFB1 on the health of people who consume
AFB1 contaminated food as evidenced by its ability to
inhibit and or deregulate the innate immune re-
sponse. In view of this it is recommended that public
education is intensified in Ghana and other develop-
ing nations of the world where AFB1 contaminated
food form a greater portion of the diets so as to re-
duce HCC and its associated deaths.
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